Evidence map›Paper›PMID 40395696›Full record

ReviewFrontiers in antibiotics2025

Non-antibiotic therapies for multidrug-resistant gastrointestinal infections: an overview of the use of probiotics, natural compounds, and bacteriophages.

Manuela Oliveira, Áurea Madureira-Carvalho, Ricardo Jorge Dinis-Oliveira, Diana Dias da Silva

Abstract readReview
In one paragraph

Review in Frontiers in antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Multidrug-ResistantPolish journal of microbiology · 2026
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Manuela OliveiraAssociate Laboratory i4HB - Institute for Health and Bioeconomy, University Institute of Health Sciences - Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Gandra, Portugal.
Áurea Madureira-CarvalhoAssociate Laboratory i4HB - Institute for Health and Bioeconomy, University Institute of Health Sciences - Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Gandra, Portugal.
Ricardo Jorge Dinis-OliveiraAssociate Laboratory i4HB - Institute for Health and Bioeconomy, University Institute of Health Sciences - Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Gandra, Portugal.
Diana Dias da SilvaAssociate Laboratory i4HB - Institute for Health and Bioeconomy, University Institute of Health Sciences - Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Gandra, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The worldwide increasing frequency and severity of multidrug-resistant gastrointestinal (MDR-GI) infections not only raises awareness of the debilities of conventional antibiotic treatments but also highlights the demand for alternative interventions. One of these alternatives is probiotics, harmless bacteria that compete with pathogenic species, which have been considered beneficial due to their therapeutic potential since they strengthen the mucosal barrier and modulate the host immune response. Other natural compounds (e.g., polyphenols, flavonoids, and essential oils) present diverse antimicrobial mechanisms, which are promising alternatives to mitigate resistant pathogens. Finally, bacteriophages, viruses that target specific bacteria, constitute a precise approach in which MDR bacteria are lysed or disrupted by the biofilms formed during colonization without compromising the normal gut microbiome. Therefore, the present manuscript provides an integrated perspective on alternative non-antibiotic therapies to manage MDR-GI infections; for this purpose, it covers aspects such as their action mechanisms, current clinical applications, and the challenges that limit their broader application in clinical practice. The potential of combining these approaches or personalizing infection treatments adjusted to patients' microbiome profiles is also discussed, aiming to enhance efficacy and reduce resistance risks. Finally, the importance of continued research and development to optimize these alternatives is also debated, addressing aspects such as the need to surpass regulatory barriers and conducting large-scale clinical trials to establish the safety and efficacy of these non-antibiotic alternatives. This overview of the current knowledge contributes to the ongoing efforts to develop sustainable strategies to combat MDR-GI infections and reduce the global burden of antibiotic resistance.

Indexed as

alternative therapiesantibiotic resistancebiofilm disruptiongut microbiotaimmune modulationmicrobial interactionsnatural compounds

Identifiers

PMID40395696
PMCPMC12089134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.